financetom
Business
financetom
/
Business
/
Science Applications Q4 Earnings Crush Estimates Helped By New Contract Volume, Stock Gains
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Science Applications Q4 Earnings Crush Estimates Helped By New Contract Volume, Stock Gains
Mar 17, 2025 5:54 AM

Science Applications International Corp ( SAIC ) shares are trading higher in premarket on Monday after the fourth-quarter FY25 earnings.

The company reported fourth-quarter sales growth of 6% year-on-year to $1.84 billion, beating the analyst consensus estimate of $1.81 billion.

Adjusted EPS of $2.57 beat the consensus estimate of $2.08.

The operating income for the quarter jumped 75% to $138 million and the operating margin expanded by 300 basis points to 7.5%.

Adjusted EBITDA increased 39% to $177 million with an adjusted EBITDA margin of 9.6%, a 230 basis points expansion.

Also Read: AstraZeneca Seals Deal For EsoBiotec To Advance Cell Therapy: Details

Net bookings for the quarter were approximately $1.3 billion, which reflects a book-to-bill ratio of approximately 0.7.  The operating cash flow for the quarter totaled $115 million, with transaction-adjusted free cash flow of $236 million.

SAIC’s estimated backlog at the end of fiscal year 2025 was approximately $21.9 billion of which $3.4 billion was funded. The company held $64 million in cash and equivalents as of January 31, 2025.

“Subsequent to quarter close, we received a $1.8 billion award for our largest recompete win in recent years, the System Software Lifecycle Engineering program. This important win along with a backlog of submitted bids valued at approximately $20 billion reflect the momentum we are building inside the company,” said CEO Toni Townes-Whitley.

Outlook: Science Applications ( SAIC ) revised the FY26 revenue outlook from $7.55 billion – $7.75 billion to $7.60 billion – $7.75 billion versus an estimate of $7.644 billion.

The company also raised the FY26 adjusted EPS outlook from $8.90 – $9.10 to $9.10 – $9.30 against an estimate of $9.07.

Price Action: SAIC shares traded higher by 9.16% at $114.00 in premarket at last check Monday.

Read Next:

Palantir Technologies Partners With RCM Company R1For AI Lab

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: WPP in Talks to Sell Flight Entertainment Provider Spafax
Market Chatter: WPP in Talks to Sell Flight Entertainment Provider Spafax
Mar 21, 2025
12:36 PM EDT, 03/21/2025 (MT Newswires) -- WPP ( WPP ) is in talks to sell its in-flight entertainment provider Spafax, which is serving top global airlines, Sky News reported Friday, citing sources. The company is in talks with bankers to manage the sale with plans to secure a price of 50 million British pounds ($64.6 million) to 75 million...
BMO changes some mortgage rules for steel, aluminum business owners due to trade war
BMO changes some mortgage rules for steel, aluminum business owners due to trade war
Mar 21, 2025
TORONTO, March 21 (Reuters) - Canada's Bank of Montreal ( BNKD ) has changed some terms of its mortgage process for steel and aluminum business owners, a memo sent to its brokers shows, as U.S. tariffs stoke uncertainties in the industry. The lender said in the memo this week that borrowers' total debt service ratio - the percentage of monthly...
Brazil's Hypera to launch an Ozempic generic in 2026, CEO says
Brazil's Hypera to launch an Ozempic generic in 2026, CEO says
Mar 21, 2025
SAO PAULO, March 21 (Reuters) - Brazilian drugmaker Hypera plans to launch next year a generic version of semaglutide, the active ingredient of Novo Nordisk's blockbuster diabetes and weight-loss drug Ozempic, Hypera's chief executive said on Friday. The patent protection for semaglutide, which is also the key ingredient of injectable obesity treatment Wegovy and the oral diabetes drug Rybelsus, expires...
Update: Cleveland-Cliffs Shares Down After Notifying Temporary Shutdown of Mines in Minnesota
Update: Cleveland-Cliffs Shares Down After Notifying Temporary Shutdown of Mines in Minnesota
Mar 21, 2025
12:33 PM EDT, 03/21/2025 (MT Newswires) -- (Updates with Cleveland-Cliffs' ( CLF ) throughout.) Cleveland-Cliffs ( CLF ) shares were down more than 2% in recent trading on Friday, a day after the company issued notices to pause operations at two of its Iron Range mines and pellet plants in Minnesota, impacting 630 workers, a company spokesperson confirmed to MT...
Copyright 2023-2026 - www.financetom.com All Rights Reserved